Jason Harris, Ph.D.

Dr. Harris is chief scientific officer at Autobahn Therapeutics.

Dr. Harris is an accomplished drug hunter, bringing more than 20 years of small molecule drug discovery and development experience to the company having led activities ranging from hit generation through oral solid dosage (OSD) development.  Prior to Autobahn, Jason was head of chemistry and CMC at Ventyx Biosciences, focused on developing therapies to modulate inflammation and innate immunity. There, he played a key role in driving Ventyx’s discovery programs from lead generation through IND-enabling studies, was co-inventor of several clinical candidates including VTX-958 and VTX-2735, and was responsible for the PR&D of VTX-002 through Phase 2 OSD formulation development.  Prior to Ventyx, he also served as a senior member of the scientific teams at Escalier Biosciences, Ignyta, Global Blood Therapeutics, and Exelixis. Dr. Harris is a co-inventor/author on more than 60 patents/applications and scientific papers, and contributor to projects that have delivered 10 clinical candidates, including two FDA approved drugs.  He holds an undergraduate degree in chemistry from Stony Brook University and a Ph.D. in organic chemistry from University of California, Irvine.